Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
Christos EmmanouilidesDepartment of Medical Oncology, Interbalkan Hospital, Thessaloniki, GreeceAbstract: Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with B-cell non-Hodgkin’s lymphoma (NHL)...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2009-10-01
|
| Schriftenreihe: | Cancer Management and Research |
| Online-Zugang: | http://www.dovepress.com/review-of-90y-ibritumomab-tiuxetan-as-first-line-consolidation-radio-i-a3657 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|